1. β₂-Agonists

   • Sandra D. Anderson

   EditorialNotes Pages: 103 - 105

2. Current issues with β₂-adrenoceptor agonists

   • Anne E. Tattersfield

   OriginalPaper Pages: 107 - 117

3. Current issues with β₂-adrenoceptor agonists

   • Gary P. Anderson

   OriginalPaper Pages: 119 - 130

4. Regulation of mast cells by β-agonists

   • Peter Peachell

   OriginalPaper Pages: 131 - 141

5. β₂-Agonists and bronchial hyperresponsiveness

   • Clive P. Page
   • Domenico Spina

   OriginalPaper Pages: 143 - 161

6. β₂-Agonists and exercise-induced asthma

   • Sandra D. Anderson
   • Corinne Caillaud
   • John D. Brannan

   OriginalPaper Pages: 163 - 180

7. Recovery from bronchoconstriction and bronchodilator tolerance

   • Sarah Haney
   • Robert J. Hancox

   OriginalPaper Pages: 181 - 196

8. Clinical concerns with inhaled β₂-agonists

   • D. W. Cockcroft

   OriginalPaper Pages: 197 - 207

9. β₂-Agonists for asthma

   • Padmaja Subbarao
   • Felix Ratjen

   OriginalPaper Pages: 209 - 218

10. Systematic review of clinical outcomes in chronic obstructive pulmonary disease

    • Shelley R. Salpeter
    • Nicholas S. Buckley

    ReviewPaper Pages: 219 - 230

11. Interactions between corticosteroids and β₂-agonists

    • Robert J. Hancox

    OriginalPaper Pages: 231 - 245

12. Pharmacogenetics of β₂-agonist drugs in asthma

    • D. Robin Taylor

    OriginalPaper Pages: 247 - 258

13. β₂-Agonists at the olympic games

    • Kenneth D. Fitch

    OriginalPaper Pages: 259 - 268

14. Serious adverse events and death associated with treatment using long-acting β-agonists

    • Fernando D. Martinez

    OriginalPaper Pages: 269 - 278

15. Concluding remarks

    • Robert J. Hancox

    OriginalPaper Pages: 279 - 287